Oxytocin and vasopressin modulate risk-taking

Area of Science:

• Neuroscience
• Behavioral Science
• Psychopharmacology

Background:

• Risk-taking is crucial for adaptive behavior.
• Oxytocin (OT) and arginine vasopressin (AVP) are neuromodulators with known social functions.
• Their influence on risk-taking behavior, particularly concerning sex, risk-valence, and social context, requires further investigation.

Purpose of the Study:

• To investigate the effects of intranasal oxytocin (OT) and arginine vasopressin (AVP) on risk-taking behavior.
• To examine how these neuropeptides modulate risk-taking in relation to sex, risk-valence (positive/negative outcomes), and social context (social-stress vs. non-social).

Main Methods:

• Twenty-nine healthy adults (14 males) participated in a within-subjects design.
• Participants completed a risk-taking task (Stunt task) under three drug conditions: OT, AVP, and placebo (PLC), administered intranasally.
• Risk-taking was assessed in both social-stress and non-social contexts.

Main Results:

• Both OT and AVP administration led to a risk-averse effect compared to placebo, reducing the betting rate.
• AVP consistently reduced risk-taking, particularly in positive risk-valence scenarios, irrespective of social context or sex.
• OT reduced risk-taking specifically in negative risk-valence scenarios, and this effect was observed only in men and within the social-stress context.

Conclusions:

• Oxytocin and arginine vasopressin modulate risk-taking behavior, extending their known functions beyond social interactions.
• The specific effects of OT and AVP on risk-taking are context-dependent, influenced by risk-valence, social setting, and sex.
• These findings highlight the complex role of neuromodulators in behavioral regulation and suggest future research directions focusing on neural targets.